ArticlemBio2022
Aminoglycoside Antibiotics Inhibit Phage Infection by Blocking an Early Step of the Infection Cycle.
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 79 citations in OpenAlex.
- When phage restriction is not immunity: Immune gates, replication-niche barriers, and assay-limited phenotypes.Engineering microbiology · 2026Article
- Phage host range: determinants, dynamics and applications.Nature reviews. Microbiology · 2026Review
- Lethal permeabilization of host bacteria to small-molecule compounds during phage penetration.Nature communications · 2026Article
- DNA-intercalating antiphage molecules trigger abortive infection through mutual destruction and synergize with bacterial immunity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- [Antibiotics and phages: effects of combined therapy on susceptibility and resistance of bacterial pathogens].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Pre-Exposure Intranasal Treatment with Neomycin Sulfate Reduces Transmission of Influenza B Virus.Antibiotics (Basel, Switzerland) · 2026Article
- LysR-type regulator LrhA promotes CRISPR-Cas immunity in Escherichia coli.Nucleic acids research · 2026Article
- A novel class of small-molecule inhibitors targeting bacteriophage infection.RSC chemical biology · 2026Article
- A satellite in the phage universe: isolation and characterization of six novelFEMS microbes · 2026Article
- Molecular characterisation of the Bacillus subtilis SpbK antiphage defence system.Nature communications · 2025Article
- Natural products influence bacteriophage infectivity.Natural product reports · 2025Review
- In silico approaches for discovering microbial antiviral defense systems.Briefings in bioinformatics · 2025Review
- Antibiotic-induced morphological changes enhance phage predation.PLoS pathogens · 2025Article
- Systematic functional assessment of anti-phage systems in their native host.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Antagonistic effect of kanamycin on kanamycin-resistant Escherichia coli infection by BtuB-targeting bacteriophages.Archives of virology · 2025Article
- Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations.The Journal of antimicrobial chemotherapy · 2025Article
- The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel, Switzerland) · 2025Review
- Extreme diversity of phage amplification rates and phage-antibiotic interactions revealed by PHORCE.PLoS biology · 2025Article
- Synergistic action of mucoactive drugs and phages againstMicrobiology spectrum · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to viral predation, bacteria have evolved a wide range of defense mechanisms, which rely mostly on proteins acting at the cellular level. Here, we show that aminoglycosides, a well-known class of antibiotics produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.